Compare · GBIO vs GOSS
GBIO vs GOSS
Side-by-side comparison of Generation Bio Co. (GBIO) and Gossamer Bio Inc. (GOSS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GBIO and GOSS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- GBIO is the larger of the two at $347.7M, about 5.1x GOSS ($68.5M).
- Over the past year, GBIO is up 25.6% and GOSS is down 90.4% - GBIO leads by 116.0 points.
- GOSS has hit the wire 4 times in the past 4 weeks while GBIO has been quiet.
- GOSS has more recent analyst coverage (25 ratings vs 8 for GBIO).
- Company
- Generation Bio Co.
- Gossamer Bio Inc.
- Price
- $5.37-6.20%
- $0.14-1.27%
- Market cap
- $347.7M
- $68.5M
- 1M return
- -1.10%
- -21.39%
- 1Y return
- +25.56%
- -90.41%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2020
- 2019
- News (4w)
- 0
- 4
- Recent ratings
- 8
- 25
Generation Bio Co.
Generation Bio Co., a genetic medicines company, develops gene therapies for the treatment of rare and prevalent diseases. The company is developing a portfolio of programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
Gossamer Bio Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
Latest GBIO
- SEC Form 15-12G filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- Amendment: SEC Form SCHEDULE 13G/A filed by Generation Bio Co.
- SEC Form EFFECT filed by Generation Bio Co.
- SEC Form 4 filed by Large owner Atlas Venture Fund X, L.P.
- Director Stehman-Breen Catherine closing all direct ownership in the company (SEC Form 4)
- SEC Form 4 filed by Director Rhodes Jason P
- Director Rowland Charles A Jr closing all direct ownership in the company (SEC Form 4)
- Director Quinn Anthony G. closing all direct ownership in the company (SEC Form 4)
- Director Nicholson Donald William closing all direct ownership in the company (SEC Form 4)
Latest GOSS
- Gossamer Bio Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits
- Amendment: SEC Form SCHEDULE 13D/A filed by Gossamer Bio Inc.
- Gossamer Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gossamer Bio, Inc. Announces Determination of Conversion Rate for 7.50% Convertible Senior Secured First Lien Notes due 2030 and Exercise Price for Purchase Warrants
- Gossamer Bio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Gossamer Bio, Inc. Announces Final Tender Results for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes
- SEC Form SCHEDULE 13D filed by Gossamer Bio Inc.
- SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.
- SEC Form DEF 14A filed by Gossamer Bio Inc.
- SEC Form SCHEDULE 13G filed by Gossamer Bio Inc.